David T. Rubin to Gastrointestinal Agents
This is a "connection" page, showing publications David T. Rubin has written about Gastrointestinal Agents.
Connection Strength
8.729
-
Etrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): two phase 3 randomised, controlled trials. Lancet Gastroenterol Hepatol. 2022 01; 7(1):17-27.
Score: 0.692
-
Cost-Effectiveness of 5-Aminosalicylate Therapy in Combination With Biologics or Tofacitinib in the Treatment of Ulcerative Colitis. Am J Gastroenterol. 2021 01 01; 116(1):125-133.
Score: 0.651
-
Ciclosporin Therapy After Infliximab Failure in Hospitalized Patients With Acute Severe Colitis is Effective and Safe. J Crohns Colitis. 2019 Sep 19; 13(9):1105-1110.
Score: 0.596
-
The Era of Anti-Tumor Necrosis Factor Is Over. What Do We Know, What Don't We Know, and What Do We Yearn to Know? Gastrointest Endosc Clin N Am. 2019 Jul; 29(3):405-419.
Score: 0.578
-
ACG Clinical Guideline: Ulcerative Colitis in Adults. Am J Gastroenterol. 2019 03; 114(3):384-413.
Score: 0.573
-
Emerging Therapies for Inflammatory Bowel Disease. Adv Ther. 2018 11; 35(11):1746-1762.
Score: 0.560
-
Higher Thioguanine Nucleotide Metabolite Levels are Associated With Better Long-term Outcomes in Patients With Inflammatory Bowel Diseases. J Clin Gastroenterol. 2018 07; 52(6):537-544.
Score: 0.548
-
Safety and Efficacy of Combination Treatment With Calcineurin Inhibitors and Vedolizumab in Patients With Refractory Inflammatory Bowel Disease. Clin Gastroenterol Hepatol. 2019 02; 17(3):486-493.
Score: 0.542
-
Safety and Efficacy of Live Measles Vaccine Administered to a Crohn's Disease Patient Receiving Vedolizumab. Am J Gastroenterol. 2016 04; 111(4):577.
Score: 0.469
-
Vedolizumab in the treatment of Crohn's disease. Expert Rev Gastroenterol Hepatol. 2016; 10(3):283-90.
Score: 0.463
-
Dose escalation of biologics in biologic-naive patients with Crohn's disease: Outcomes from the ODESSA-CD study. J Manag Care Spec Pharm. 2024 Nov; 30(11):1276-1287.
Score: 0.212
-
Real-World Persistence of Successive Biologics in Patients With Inflammatory Bowel Disease: Findings From ROTARY. Inflamm Bowel Dis. 2024 Oct 03; 30(10):1776-1787.
Score: 0.211
-
Evaluation of adverse clinical outcomes in patients with inflammatory bowel disease receiving different sequences of first- and second-line biologic treatments: findings from ROTARY. BMC Gastroenterol. 2024 Sep 17; 24(1):314.
Score: 0.211
-
Risankizumab Effectiveness and Safety in Crohn's Disease: Real-world Data From a Large Tertiary Center. Clin Gastroenterol Hepatol. 2024 Jun; 22(6):1336-1338.e2.
Score: 0.200
-
A Prospective Trial with Long Term Follow-up of Patients With Severe, Steroid-Resistant Ulcerative Colitis Who Received Induction Therapy With Cyclosporine and Were Maintained With Vedolizumab. Inflamm Bowel Dis. 2022 10 03; 28(10):1549-1554.
Score: 0.184
-
Treatment of pouchitis, Crohn's disease, cuffitis, and other inflammatory disorders of the pouch: consensus guidelines from the International Ileal Pouch Consortium. Lancet Gastroenterol Hepatol. 2022 01; 7(1):69-95.
Score: 0.173
-
Vedolizumab and Anti-Tumour Necrosis Factor a Real-World Outcomes in Biologic-Naïve Inflammatory Bowel Disease Patients: Results from the EVOLVE Study. J Crohns Colitis. 2021 Oct 07; 15(10):1694-1706.
Score: 0.172
-
Ustekinumab is more effective than azathioprine to prevent endoscopic postoperative recurrence in Crohn's disease. United European Gastroenterol J. 2021 06; 9(5):552-560.
Score: 0.167
-
Outcome of elective switching to vedolizumab in inflammatory bowel disease patients under tumor necrosis factor antagonist-maintained clinical remission. J Gastroenterol Hepatol. 2019 Dec; 34(12):2090-2095.
Score: 0.147
-
Incidence of Arthritis/Arthralgia in Inflammatory Bowel Disease with Long-term Vedolizumab Treatment: Post Hoc Analyses of the GEMINI Trials. J Crohns Colitis. 2019 Jan 01; 13(1):50-57.
Score: 0.142
-
Efficacy of Vedolizumab in Fistulising Crohn's Disease: Exploratory Analyses of Data from GEMINI 2. J Crohns Colitis. 2018 Apr 27; 12(5):621-626.
Score: 0.135
-
The Use of Vedolizumab in Preventing Postoperative Recurrence of Crohn's Disease. Inflamm Bowel Dis. 2018 02 15; 24(3):502-509.
Score: 0.133
-
Long-term Efficacy of Vedolizumab for Crohn's Disease. J Crohns Colitis. 2017 Apr 01; 11(4):412-424.
Score: 0.126
-
Long-term Efficacy of Vedolizumab for Ulcerative Colitis. J Crohns Colitis. 2017 Apr 01; 11(4):400-411.
Score: 0.126
-
Effects of vedolizumab on health-related quality of life in patients with ulcerative colitis: results from the randomised GEMINI 1 trial. Aliment Pharmacol Ther. 2017 01; 45(2):264-275.
Score: 0.122
-
Efficacy of Vedolizumab Induction and Maintenance Therapy in Patients With Ulcerative Colitis, Regardless of Prior Exposure to Tumor Necrosis Factor Antagonists. Clin Gastroenterol Hepatol. 2017 02; 15(2):229-239.e5.
Score: 0.121
-
Patients with Ulcerative Colitis Are More Concerned About Complications of Their Disease than Side Effects of Medications. Inflamm Bowel Dis. 2016 Apr; 22(4):940-7.
Score: 0.117
-
Optimal doses of methotrexate combined with anti-TNF therapy to maintain clinical remission in inflammatory bowel disease. J Crohns Colitis. 2015 Apr; 9(4):312-7.
Score: 0.108
-
Rescue therapy with cyclosporine or infliximab is not associated with an increased risk for postoperative complications in patients hospitalized for severe steroid-refractory ulcerative colitis. Inflamm Bowel Dis. 2014 Jan; 20(1):14-20.
Score: 0.100
-
Impact of ulcerative colitis from patients' and physicians' perspectives: Results from the UC: NORMAL survey. Inflamm Bowel Dis. 2009 Apr; 15(4):581-8.
Score: 0.072
-
Long-term safety of vedolizumab for inflammatory bowel disease. Aliment Pharmacol Ther. 2020 10; 52(8):1353-1365.
Score: 0.040
-
Efficacy of biosimilar infliximab CT-P13 among inpatients with severe steroid-refractory colitis. Int J Colorectal Dis. 2020 Nov; 35(11):2113-2116.
Score: 0.039